Abstract:Importance: Acute myeloid leukemia (AML) is a clonal hematopoietic cancer that disrupts normal hematopoiesis, ultimately leading to bone marrow failure and death. The annual incidence rate of AML is 4.1 per 100 000 people in the US and is higher in patients older than 65 years. Acute myeloid leukemia includes numerous subgroups with heterogeneous molecular profiles, treatment response, and prognosis. This review discusses the evidence supporting frontline therapies in AML, the major principles that guide therapy, and progress with molecularly targeted therapy. Observations: Acute myeloid leukemia is a genetically complex, dynamic disease. The most commonly altered genes include FLT3, NPM1, DNMT3A, IDH1, IDH2, TET2, RUNX1, NRAS, and TP53. The incidence of these alterations varies by patient age, history of antecedent hematologic cancer, and previous exposure to chemotherapy and/or radiotherapy for any cancer. Since 2010, molecular data have been incorporated into AML prognostication, gradually leading to incorporation of targeted therapies into the initial treatment approach of induction chemotherapy and subsequent management. The first molecularly targeted inhibitor, midostaurin, was approved to treat patients with AML with FLT3 variants in 2017. Since then, the understanding of the molecular pathogenesis of AML has expanded, allowing the identification of additional potential targets for drug therapy, treatment incorporation of molecularly targeted therapies (midostaurin, gilteritinib, and quizartinib targeting FLT3 variants; ivosidenib and olutasidenib targeting IDH1 variants, and enasidenib targeting IDH2), and identification of rational combination regimens. The approval of hypomethylating agents combined with venetoclax has revolutionized the therapy of AML in older adults, extending survival over monotherapy. Additionally, patients are now referred for hematopoietic cell transplant on a more rational basis. Conclusions and relevance: In the era of genomic medicine, AML treatment is customized to the patient's comorbidities and AML genomic profile.

Interdisciplinary Management of Acute Leukemia Across the Continuum of Care

Contemporary Management of Acute Myeloid Leukemia: A Review

Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario

Advances in acute myeloid leukemia

Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?

Risk Assessment and Risk-Adapted Treatment Selection: A Case-Based Approach for Chronic Lymphocytic Leukemia

Integrating Emerging Data Into Clinical Practice: A Case-Based Approach for Multiple Myeloma

Novel Approaches for the Interim Management of Relapsed/Refractory Acute Lymphocytic Leukemia: A Case-Study Compendium

Optimizing Treatment of Chronic Lymphocytic Leukemia

The Landscape of Novel Strategies for Acute Myeloid Leukemia Treatment: Therapeutic Trends, Challenges, and Future Directions

Management of Acute Promyelocytic Leukemia: Updated Recommendations from an Expert Panel of the European LeukemiaNet.

The Importance of Multidisciplinary Team Management of Patients with Non-Small-Cell Lung Cancer

Novel Management Options for Adult Patients With Progressive Acute Lymphoblastic Leukemia: A Case-Study Compendium

Leukemic stem cells and advances in hematopoietic stem cell transplantation for acute myeloid leukemia: a narrative review of clinical trials

The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms

Acute Myeloid Leukemia: Challenges in Delivering End-of-Life Care

Contemporary Management of Acute Myeloid Leukemia

How I Manage Acute Respiratory Failure in Patients with Hematological Malignancies

Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia

Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress

Management of patients with acute promyelocytic leukemia